# IGC Pharma, Inc.: financial statements, quarterly

IGC · NYSE · CIK 1326205 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/igc.md) · [Financials](/companies/igc/financials.md) · [Filings](/companies/igc/filings.md) · [Insiders](/companies/igc/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/igc/financials.md?period=annual).

## Income statement

| Line item | Unit | Q2 FY2024 (2023-09-30) | Q3 FY2024 (2023-12-31) | Q4 FY2024 (2024-03-31) | Q1 FY2025 (2024-06-30) | Q2 FY2025 (2024-09-30) | Q3 FY2025 (2024-12-31) | Q4 FY2025 (2025-03-31) | Q1 FY2026 (2025-06-30) | Q2 FY2026 (2025-09-30) | Q3 FY2026 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2027 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $k | [291](/filings/0001185185-24-001096.md) | [204](/filings/0001185185-25-000137.md) | [295 d](/filings/0001185185-25-000706.md) | [272](/filings/0001185185-25-000997.md) | [412](/filings/0001185185-25-001752.md) | [257](/filings/0001185185-25-000137.md) | [330](/filings/0001185185-26-001885.md) | [328](/filings/0001185185-26-003544.md) | [191](/filings/0001185185-25-001752.md) | [350 d](/filings/0001185185-26-000941.md) | [317](/filings/0001185185-26-001885.md) | [265](/filings/0001185185-26-003544.md) |
| Cost of revenue | $k | [117](/filings/0001185185-24-001096.md) | [71.0](/filings/0001185185-25-000137.md) | [124 d](/filings/0001185185-25-000706.md) | [109](/filings/0001185185-25-000997.md) | [214](/filings/0001185185-25-001752.md) | [153](/filings/0001185185-25-000137.md) | [176](/filings/0001185185-26-001885.md) | [174](/filings/0001185185-26-003544.md) | [92.0](/filings/0001185185-25-001752.md) | [306 d](/filings/0001185185-26-000941.md) | [262](/filings/0001185185-26-001885.md) | [217](/filings/0001185185-26-003544.md) |
| Gross profit | $k | [174](/filings/0001185185-24-001096.md) | [133](/filings/0001185185-25-000137.md) | [171 d](/filings/0001185185-25-000706.md) | [163](/filings/0001185185-25-000997.md) | [198](/filings/0001185185-25-001752.md) | [104](/filings/0001185185-25-000137.md) | [154](/filings/0001185185-26-001885.md) | [154](/filings/0001185185-26-003544.md) | [99.0](/filings/0001185185-25-001752.md) | [44.0 d](/filings/0001185185-26-000941.md) | [55.0](/filings/0001185185-26-001885.md) | [48.0](/filings/0001185185-26-003544.md) |
| Research and development | $k | [1,268](/filings/0001185185-24-001096.md) | [903](/filings/0001185185-25-000137.md) | [855 d](/filings/0001185185-25-000706.md) | [889](/filings/0001185185-25-000997.md) | [917](/filings/0001185185-25-001752.md) | [852](/filings/0001185185-25-000137.md) | [997](/filings/0001185185-26-001885.md) | [851](/filings/0001185185-26-003544.md) | [1,588](/filings/0001185185-25-001752.md) | [1,482 d](/filings/0001185185-26-000941.md) | [1,272](/filings/0001185185-26-001885.md) | [1,390](/filings/0001185185-26-003544.md) |
| Selling, general and administrative | $k | [1,397](/filings/0001185185-24-001096.md) | [2,228](/filings/0001185185-25-000137.md) | [1,486 d](/filings/0001185185-25-000706.md) | [1,670](/filings/0001185185-25-000997.md) | [1,041](/filings/0001185185-25-001752.md) | [1,130](/filings/0001185185-25-000137.md) | [570](/filings/0001185185-26-001885.md) | [1,208](/filings/0001185185-26-003544.md) | [1,410](/filings/0001185185-25-001752.md) | [1,503 d](/filings/0001185185-26-000941.md) | [1,241](/filings/0001185185-26-001885.md) | [1,442](/filings/0001185185-26-003544.md) |
| Operating income | $k | [(2,491)](/filings/0001185185-24-001096.md) | [(2,998)](/filings/0001185185-25-000137.md) | [(2,170) d](/filings/0001185185-25-000706.md) | [(2,396)](/filings/0001185185-25-000997.md) | [(1,760)](/filings/0001185185-25-001752.md) | [(1,878)](/filings/0001185185-25-000137.md) | [(1,413)](/filings/0001185185-26-001885.md) | [(1,905)](/filings/0001185185-26-003544.md) | [(2,899)](/filings/0001185185-25-001752.md) | [(2,941) d](/filings/0001185185-26-000941.md) | [(2,458)](/filings/0001185185-26-001885.md) | [(2,784)](/filings/0001185185-26-003544.md) |
| Interest expense | $k | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Income tax | $k | [0.0](/filings/0001185185-24-001096.md) | [0.0](/filings/0001185185-25-000137.md) | [0.0 d](/filings/0001185185-25-000706.md) | [0.0](/filings/0001185185-25-000997.md) | [0.0](/filings/0001185185-25-001752.md) | [0.0](/filings/0001185185-25-000137.md) | [0.0](/filings/0001185185-26-001885.md) | [0.0](/filings/0001185185-26-003544.md) | [0.0](/filings/0001185185-25-001752.md) | [0.0 d](/filings/0001185185-26-000941.md) | [0.0](/filings/0001185185-26-001885.md) | [0.0](/filings/0001185185-26-003544.md) |
| Net income | $k | [(2,451)](/filings/0001185185-24-001096.md) | [(5,589)](/filings/0001185185-25-000137.md) | [(2,885) d](/filings/0001185185-25-000706.md) | [(2,378)](/filings/0001185185-25-000997.md) | [(1,717)](/filings/0001185185-25-001752.md) | [(1,829)](/filings/0001185185-25-000137.md) | [(1,198)](/filings/0001185185-26-001885.md) | [(1,599)](/filings/0001185185-26-003544.md) | [(1,821)](/filings/0001185185-25-001752.md) | [(726) d](/filings/0001185185-26-000941.md) | [(2,402)](/filings/0001185185-26-001885.md) | [(2,936)](/filings/0001185185-26-003544.md) |
| Diluted EPS | $ per share | [(0.05)](/filings/0001185185-24-001096.md) | [(0.09)](/filings/0001185185-25-000137.md) | not reported | [(0.03)](/filings/0001185185-25-000997.md) | [(0.02)](/filings/0001185185-25-001752.md) | [(0.02)](/filings/0001185185-25-000137.md) | [(0.02)](/filings/0001185185-26-001885.md) | [(0.02)](/filings/0001185185-26-003544.md) | [(0.02)](/filings/0001185185-25-001752.md) | not reported | [(0.02)](/filings/0001185185-26-001885.md) | [(0.03)](/filings/0001185185-26-003544.md) |
| Basic EPS | $ per share | [(0.05)](/filings/0001185185-24-001096.md) | [(0.09)](/filings/0001185185-25-000137.md) | not reported | [(0.03)](/filings/0001185185-25-000997.md) | [(0.02)](/filings/0001185185-25-001752.md) | [(0.02)](/filings/0001185185-25-000137.md) | [(0.02)](/filings/0001185185-26-001885.md) | [(0.02)](/filings/0001185185-26-003544.md) | [(0.02)](/filings/0001185185-25-001752.md) | not reported | [(0.02)](/filings/0001185185-26-001885.md) | [(0.03)](/filings/0001185185-26-003544.md) |

- Revenue: us-gaap:Revenues
- Cost of revenue: us-gaap:CostOfRevenue
- Gross profit: us-gaap:GrossProfit
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Selling, general and administrative: us-gaap:SellingGeneralAndAdministrativeExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: not reported
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q2 FY2024 (2023-09-30) | Q3 FY2024 (2023-12-31) | FY2024 (2024-03-31) | Q1 FY2025 (2024-06-30) | Q2 FY2025 (2024-09-30) | Q3 FY2025 (2024-12-31) | FY2025 (2025-03-31) | Q1 FY2026 (2025-06-30) | Q2 FY2026 (2025-09-30) | FY2026 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2027 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [3.0](/filings/0001185185-23-001163.md) | [1.4](/filings/0001185185-24-000160.md) | [1.2](/filings/0001185185-25-000706.md) | [1.8](/filings/0001185185-24-000766.md) | [1.5](/filings/0001185185-24-001096.md) | [0.5](/filings/0001185185-25-000137.md) | [0.4](/filings/0001185185-26-000941.md) | [0.5](/filings/0001185185-25-000997.md) | [1.1](/filings/0001185185-25-001752.md) | [0.9](/filings/0001185185-26-003544.md) | [0.2](/filings/0001185185-26-001885.md) | [0.3](/filings/0001185185-26-003544.md) |
| Current assets | $m | [6.1](/filings/0001185185-23-001163.md) | [3.6](/filings/0001185185-24-000160.md) | [3.7](/filings/0001185185-25-000706.md) | [4.4](/filings/0001185185-24-000766.md) | [4.3](/filings/0001185185-24-001096.md) | [3.1](/filings/0001185185-25-000137.md) | [2.9](/filings/0001185185-26-000941.md) | [2.2](/filings/0001185185-25-000997.md) | [2.0](/filings/0001185185-25-001752.md) | [1.8](/filings/0001185185-26-003544.md) | [1.1](/filings/0001185185-26-001885.md) | [1.3](/filings/0001185185-26-003544.md) |
| Total assets | $m | [16.5](/filings/0001185185-23-001163.md) | [11.3](/filings/0001185185-24-000160.md) | [9.9](/filings/0001185185-25-000706.md) | [10.6](/filings/0001185185-24-000766.md) | [10.4](/filings/0001185185-24-001096.md) | [9.1](/filings/0001185185-25-000137.md) | [8.7](/filings/0001185185-26-000941.md) | [7.9](/filings/0001185185-25-000997.md) | [9.7](/filings/0001185185-25-001752.md) | [9.7](/filings/0001185185-26-003544.md) | [9.2](/filings/0001185185-26-001885.md) | [9.5](/filings/0001185185-26-003544.md) |
| Current liabilities | $m | [2.1](/filings/0001185185-23-001163.md) | [1.9](/filings/0001185185-24-000160.md) | [2.3](/filings/0001185185-25-000706.md) | [2.5](/filings/0001185185-24-000766.md) | [2.8](/filings/0001185185-24-001096.md) | [2.7](/filings/0001185185-25-000137.md) | [2.3](/filings/0001185185-26-000941.md) | [1.7](/filings/0001185185-25-000997.md) | [1.5](/filings/0001185185-25-001752.md) | [2.2](/filings/0001185185-26-003544.md) | [2.9](/filings/0001185185-26-001885.md) | [3.2](/filings/0001185185-26-003544.md) |
| Total liabilities | $m | [2.4](/filings/0001185185-23-001163.md) | [2.2](/filings/0001185185-24-000160.md) | [2.6](/filings/0001185185-25-000706.md) | [2.7](/filings/0001185185-24-000766.md) | [3.0](/filings/0001185185-24-001096.md) | [2.8](/filings/0001185185-25-000137.md) | [2.4](/filings/0001185185-26-000941.md) | [1.9](/filings/0001185185-25-000997.md) | [1.7](/filings/0001185185-25-001752.md) | [2.3](/filings/0001185185-26-003544.md) | [3.1](/filings/0001185185-26-001885.md) | [3.4](/filings/0001185185-26-003544.md) |
| Long-term debt | $m | [0.1](/filings/0001185185-23-001163.md) | [0.1](/filings/0001185185-24-000160.md) | [0.1](/filings/0001185185-25-000706.md) | [0.1](/filings/0001185185-24-000766.md) | [0.1](/filings/0001185185-24-001096.md) | [0.1](/filings/0001185185-25-000137.md) | [0.1](/filings/0001185185-26-000941.md) | [0.1](/filings/0001185185-25-000997.md) | [0.1](/filings/0001185185-25-001752.md) | [0.1](/filings/0001185185-26-000941.md) | not reported | not reported |
| Short-term borrowings | $m | [0.0](/filings/0001185185-23-001163.md) | [0.0](/filings/0001185185-24-000160.md) | [0.0](/filings/0001185185-25-000706.md) | [0.0](/filings/0001185185-24-000766.md) | [0.0](/filings/0001185185-24-001096.md) | [0.0](/filings/0001185185-25-000137.md) | [0.0](/filings/0001185185-26-000941.md) | [0.0](/filings/0001185185-25-000997.md) | [0.0](/filings/0001185185-25-001752.md) | [0.0](/filings/0001185185-26-000941.md) | not reported | not reported |
| Shareholders' equity | $m | [14.1](/filings/0001185185-25-000137.md) | [9.1](/filings/0001185185-25-000137.md) | [7.3](/filings/0001185185-26-000941.md) | [7.9](/filings/0001185185-25-001752.md) | [7.4](/filings/0001185185-25-001752.md) | [6.3](/filings/0001185185-26-003544.md) | [6.3](/filings/0001185185-26-003544.md) | [6.1](/filings/0001185185-26-003544.md) | [8.1](/filings/0001185185-25-001752.md) | [7.4](/filings/0001185185-26-003544.md) | [6.1](/filings/0001185185-26-003544.md) | [6.1](/filings/0001185185-26-003544.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: us-gaap:LongTermDebtNoncurrent
- Short-term borrowings: us-gaap:ShortTermBorrowings
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q2 FY2024 (2023-09-30) | Q3 FY2024 (2023-12-31) | Q4 FY2024 (2024-03-31) | Q1 FY2025 (2024-06-30) | Q2 FY2025 (2024-09-30) | Q3 FY2025 (2024-12-31) | Q4 FY2025 (2025-03-31) | Q1 FY2026 (2025-06-30) | Q2 FY2026 (2025-09-30) | Q3 FY2026 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2027 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $k | [(1,618) d](/filings/0001185185-24-001096.md) | [(1,587) d](/filings/0001185185-25-000137.md) | [(526) d](/filings/0001185185-25-000706.md) | [(1,752)](/filings/0001185185-25-000997.md) | [(996) d](/filings/0001185185-25-001752.md) | [(1,317) d](/filings/0001185185-26-000941.md) | [(730)](/filings/0001185185-26-001885.md) | [(1,407)](/filings/0001185185-25-000997.md) | [(2,090) d](/filings/0001185185-25-001752.md) | [(1,223) d](/filings/0001185185-26-000941.md) | [(1,223)](/filings/0001185185-26-001885.md) | [(1,350) d](/filings/0001185185-26-003544.md) |
| Capital expenditure | $k | [35.0 d](/filings/0001185185-24-001096.md) | [68.0 d](/filings/0001185185-25-000137.md) | [15.0 d](/filings/0001185185-25-000706.md) | [38.0](/filings/0001185185-25-000997.md) | [29.0 d](/filings/0001185185-25-001752.md) | [27.0 d](/filings/0001185185-26-000941.md) | [18.0](/filings/0001185185-26-001885.md) | [8.0](/filings/0001185185-25-000997.md) | [29.0 d](/filings/0001185185-25-001752.md) | [12.0 d](/filings/0001185185-26-000941.md) | [1.0](/filings/0001185185-26-001885.md) | [5.0 d](/filings/0001185185-26-003544.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

## Shares

| Line item | Unit | Q2 FY2018 (2017-09-30) | Q3 FY2018 (2017-12-31) | Q2 FY2024 (2023-09-30) | Q3 FY2024 (2023-12-31) | Q1 FY2025 (2024-06-30) | Q2 FY2025 (2024-09-30) | Q3 FY2025 (2024-12-31) | Q4 FY2025 (2025-03-31) | Q1 FY2026 (2025-06-30) | Q2 FY2026 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2027 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [29.1](/filings/0001185185-17-002428.md) | [28.2](/filings/0001185185-18-000276.md) | [54.3](/filings/0001185185-24-001096.md) | [63.7](/filings/0001185185-25-000137.md) | [72.8](/filings/0001185185-25-000997.md) | [76.0](/filings/0001185185-25-001752.md) | [77.6](/filings/0001185185-25-000137.md) | [79.7](/filings/0001185185-26-001885.md) | [83.0](/filings/0001185185-26-003544.md) | [90.5](/filings/0001185185-25-001752.md) | [98.2](/filings/0001185185-26-001885.md) | [100](/filings/0001185185-26-003544.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 103,384,008 at 2026-08-05, from the cover of the [10-Q filed 2026-08-14](/filings/0001185185-26-003544.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:37 ET. No prices; not investment advice.